Provided by Tiger Trade Technology Pte. Ltd.

ORUKA THERAPEUTICS INC

84.52
+1.101.32%
Post-market: 84.520.00000.00%19:30 EDT
Volume:581.50K
Turnover:49.09M
Market Cap:5.60B
PE:-41.76
High:86.00
Open:84.81
Low:83.33
Close:83.42
52wk High:115.52
52wk Low:19.04
Shares:66.21M
Float Shares:56.88M
Volume Ratio:0.55
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0242
EPS(LYR):-1.8483
ROE:-18.23%
ROA:-12.95%
PB:5.03
PE(LYR):-45.73

Loading ...

Oruka Therapeutics (ORKA) Just Gave Investors A Fresh Question

Simply Wall St.
·
Yesterday

Oruka Therapeutics CEO Lawrence Klein Disposes of $2.09 Million in Common Shares

Reuters
·
Yesterday

Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says

MT Newswires Live
·
Sep 25

ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors

TIPRANKS
·
Sep 25

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)

TIPRANKS
·
Sep 24

Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

TIPRANKS
·
Sep 24

Oruka Falls After Reporting Mid-Stage Data for Psoriasis Drug

Reuters
·
Sep 23

Oruka Therapeutics announces Week 28 results for ORKA-001

TIPRANKS
·
Sep 23

Oruka Says ORKA-001 Hits 71.4% PASI 100 at Week 28 in Everlast-a Psoriasis Trial

Reuters
·
Sep 23

Oruka Therapeutics - Orka-001 Maintains Favorable Safety and Tolerability Profile Through Week 28

THOMSON REUTERS
·
Sep 23

Oruka Therapeutics - 52-Week Everlast-a Data Expected in December 2026

THOMSON REUTERS
·
Sep 23

Oruka Therapeutics - Two Serious Adverse Events Reported, Neither Deemed Drug Related

THOMSON REUTERS
·
Sep 23

Oruka Therapeutics Announces Positive Week 28 Data for Orka-001 from the Ongoing Everlast-a Trial Showing Deepening of Responses Without Additional Dosing

THOMSON REUTERS
·
Sep 23

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

GlobeNewswire
·
Sep 23

Oruka Therapeutics General Counsel Paul Quinlan Disposes of USD 931,699.56 in Common Shares

Reuters
·
Sep 22

Oruka Therapeutics to Attend Morgan Stanley Global Healthcare Conference

Reuters
·
Sep 10

Oruka Therapeutics CEO Lawrence Klein Sells USD 6.85 Million in Common Shares

Reuters
·
Sep 02

Oruka Therapeutics Files Form 3 for Chief Commercial Officer Larry Todd Edwards

Reuters
·
Aug 26

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

Press Release: Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer

Dow Jones
·
Aug 25